TENXNasdaqPharmaceutical PreparationsFiscal year ends December 31
TENAX THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$1.52+0.16 (+11.76%)
Close on Oct 19, 2026
- Market cap
- $77.32M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
81.1%
30M of 37M shares
Institutional holders
111
45 new, 13 sold out
Net institutional buying
10M
In Q2 2026
Insider trades, 12 months
26 buys · 0 sales
Net bought $5.14M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Janus Henderson Group PLC | 623,733 | 9.99% | 13G (passive) | Nov 28, 2025 |
| VHCP Management EG, LLC | 552,970 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Daniel Schneeberger | 5,257,389 | 14.00% | 13G (passive) | Aug 31, 2026 |
| VHCP Co-Investment Holdings III, LLC | 449,492 | 9.90% | 13G (passive) amendment | Jun 30, 2025 |
| Lind Global Fund II LP | 442,480 | 6.62% | 13G (passive) amendment | Dec 31, 2025 |
| Venrock Healthcare Capital Partners EG, L.P. | 417,541 | 9.90% | 13G (passive) amendment | Mar 31, 2025 |
| Abigail P. Johnson | 3,942,373 | 14.90% | 13G (passive) | Jun 30, 2026 |
| Vivo Opportunity Fund Holdings, L.P. | 3,458,327 | 9.00% | 13G (passive) amendment | Jun 30, 2026 |
| Integrated Core Strategies (US) LLC | 313,712 | 6.90% | 13G (passive) amendment | Sep 30, 2025 |
| Bvf Partners L P/Il | 3,110,363 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Roderick Wong | 2,866,654 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Sphera Global Healthcare GP Ltd. | 2,663,296 | 7.09% | 13G (passive) amendment | Sep 30, 2026 |
| Ryan Wilder | 2,470,096 | 9.90% | 13G (passive) | Sep 30, 2024 |
| Dellora Investments LP | 2,400,000 | 6.40% | 13G (passive) amendment | Oct 2, 2026 |
| Israel A. Englander | 2,156,891 | 5.80% | 13G (passive) | Aug 13, 2026 |
| Sphera Global Healthcare Management LP | 1,993,496 | 5.33% | 13G (passive) | Aug 17, 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 1,955,105 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
| Lampert Mark N | 1,908,722 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Phillip Gross | 1,899,495 | 6.81% | 13G (passive) amendment | Jun 30, 2026 |
| RTW Investments, LP | 1,867,630 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TENX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 3,942,373 | 10.53% | $57.36M | +3,619,773 | 0.00% |
| Vivo Capital, LLC | 2,500,000 | 6.68% | $36.38M | +2,291,667 | 3.32% |
| BlackRock, Inc. | 1,727,988 | 4.62% | $25.14M | +1,711,011 | 0.00% |
| Perceptive Advisors LLC | 1,700,000 | 4.54% | $24.74M | +252,218 | 0.37% |
| Vanguard Capital Management LLC | 1,147,121 | 3.07% | $16.69M | +883,700 | 0.00% |
| Millennium Management LLC | 876,230 | 2.34% | $12.75M | +342,341 | 0.00% |
| Ikarian Capital, LLC | 787,600 | 2.10% | $11.46M | −230,000 | 1.23% |
| Candriam S.C.A. | 749,588 | 2.00% | $10.90M | New | 0.05% |
| Citadel Advisors LLC | 728,561 | 1.95% | $10.60M | +576,045 | 0.00% |
| Rtw Investments, LP | 696,570 | 1.86% | $10.14M | +326,324 | 0.09% |
| Stonepine Capital Management, LLC | 660,000 | 1.76% | $9.60M | −315,200 | 5.42% |
| Geode Capital Management, LLC | 639,537 | 1.71% | $9.31M | +570,377 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 607,660 | 1.62% | $8.84K | −2,343,456 | 0.00% |
| Marshall Wace, Llp | 585,578 | 1.56% | $8.52M | +233,006 | 0.01% |
| Braidwell LP | 584,412 | 1.56% | $8.50M | New | 0.31% |
| Point72 Asset Management, L.P. | 556,761 | 1.49% | $8.10M | +22,796 | 0.01% |
| Velan Capital Investment Management LP | 549,985 | 1.47% | $8.00M | −33,348 | 4.87% |
| Adage Capital Partners Gp, L.L.C. | 540,126 | 1.44% | $7.86M | – | 0.01% |
| Woodline Partners LP | 531,254 | 1.42% | $7.73M | +207,343 | 0.02% |
| State Street Corp | 510,814 | 1.36% | $7.43M | +481,824 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 111 | 30M | 81.1% | 45 / 39 | 14 / 13 | 19M | 8M |
| Q1 2026 | 80 | 22M | 57.9% | 34 / 26 | 6 / 1 | 15M | 0M |
| Q4 2025 | 49 | 7M | 18.9% | 20 / 12 | 3 / 5 | 3M | 0M |
| Q3 2025 | 34 | 5M | 12.6% | 11 / 9 | 2 / 3 | 3M | 0M |
| Q2 2025 | 26 | 2M | 6.0% | 3 / 6 | 4 / 0 | 0M | 0M |
| Q1 2025 | 23 | 2M | 5.4% | 4 / 5 | 3 / 2 | 1M | 0M |
| Q4 2024 | 21 | 1M | 3.6% | 7 / 2 | 3 / 5 | 0M | 0M |
| Q3 2024 | 19 | 1M | 3.3% | 13 / 3 | 1 / 4 | 1M | 0M |
| Q2 2024 | 11 | 0M | 0.1% | 4 / 2 | 1 / 2 | 0M | 0M |
| Q1 2024 | 9 | 0M | 0.0% | 9 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of TENX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 852,259 | 2.28% | $12.40M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 648,782 | 1.73% | $9.44M | 0.01% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 445,976 | 1.19% | $6.49M | 0.05% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 445,100 | 1.19% | $6.10M | 0.28% | Jul 31, 2026 |
| Nuveen Quant Small Cap Equity Fund | 432,200 | 1.15% | $5.92M | 0.15% | Jul 31, 2026 |
| Fidelity Small Cap Discovery Fund | 335,016 | 0.90% | $4.59M | 0.20% | Jul 31, 2026 |
| Fidelity Series Small Cap Discovery Fund | 299,100 | 0.80% | $4.10M | 0.21% | Jul 31, 2026 |
| Fidelity Series Small Cap Core Fund | 282,400 | 0.75% | $3.87M | 0.25% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 277,850 | 0.74% | $4.04M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 275,703 | 0.74% | $3.78M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 228,271 | 0.61% | $3.32M | 0.02% | Jun 30, 2026 |
| BNY Mellon Small/Mid Cap Growth Fund | 125,362 | 0.33% | $1.82M | 0.21% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 83,907 | 0.22% | $1.22M | 0.08% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 76,941 | 0.21% | $913.29K | 0.00% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 68,684 | 0.18% | $940.97K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Christopher Thomas Giordano | CEO, Director | 22,174 | 0.06% | Sep 15, 2026 |
| Stuart Rich | Chief Medical Officer, Director | 12,654 | 0.03% | Jan 13, 2026 |
| Thomas R. Staab Ii | Chief Financial Officer | 15,675 | 0.04% | Sep 15, 2026 |
| Thomas McGauley | Interim CFO | 8,000 | 0.02% | Feb 3, 2026 |
| Declan Doogan | Director | 55,274 | 0.15% | Sep 17, 2026 |
| Michael H. Davidson | Director | 2,881 | 0.01% | Jan 13, 2026 |
| Gerald T. Proehl | Director | 1,667 | 0.00% | Jan 13, 2026 |
| June Sherie Almenoff | Director | 3,986 | 0.01% | Jan 13, 2026 |
| Robyn Hunter | Director | 0 | – | Jan 13, 2026 |
| ADAR1 Capital Management, LLC | 10% owner | 6,524,151 | 17.43% | Sep 8, 2026 |
| Daniel Schneeberger | 10% owner | 5,624,151 | 15.03% | Sep 8, 2026 |
| Investments LP Dellora | – | 351,071 | 0.94% | Mar 12, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Declan Doogan Director | Sep 16, 2026 | Buy | +53,000 | $1.92 | $101.76K | 55,274 |
| Christopher Thomas Giordano CEO, Director | Sep 15, 2026 | Buy | +4,850 | $1.82 | $8.83K | 22,174 |
| Christopher Thomas Giordano CEO, Director | Sep 11, 2026 | Buy | +6,000 | $1.88 | $11.28K | 17,324 |
| Thomas R. Staab Ii Chief Financial Officer | Sep 11, 2026 | Buy | +5,675 | $1.94 | $11.01K | 15,675 |
| ADAR1 Capital Management, LLC 10% owner | Sep 3, 2026 | Buy | +900,000 | $1.78 | $1.60M | 6,524,151 |
| Daniel Schneeberger 10% owner | Sep 2, 2026 | Buy | +187,704 | $1.80 | $337.87K | 5,624,151 |
| Daniel Schneeberger 10% owner | Sep 1, 2026 | Buy | +179,058 | $1.80 | $322.30K | 5,436,447 |
| Daniel Schneeberger 10% owner | Aug 31, 2026 | Buy | +403,571 | $1.79 | $722.39K | 5,257,389 |
| Daniel Schneeberger 10% owner | Aug 24, 2026 | Buy | +107,374 | $1.75 | $187.90K | 4,853,818 |
| Daniel Schneeberger 10% owner | Aug 21, 2026 | Buy | +716,369 | $1.77 | $1.27M | 4,746,444 |
| Daniel Schneeberger 10% owner | Aug 20, 2026 | Buy | +202,124 | $1.78 | $359.78K | 4,030,075 |
| Christopher Thomas Giordano CEO, Director | Jul 13, 2026 | Option exercise | +8,500 | $5.94 | $50.49K | 11,324 |
| Christopher Thomas Giordano CEO, Director | Jul 13, 2026 | Option exercise | +219 | $3.55 | $777 | 2,824 |
| Thomas R. Staab Ii Chief Financial Officer | May 11, 2026 | Award | +10,000 | – | – | 10,000 |
| Stuart Rich Chief Medical Officer, Director | Dec 9, 2025 | Buy | +2,500 | $10.22 | $25.55K | 5,266 |
| Stuart Rich Chief Medical Officer, Director | Dec 8, 2025 | Buy | +2,500 | $10.10 | $25.25K | 5,000 |
| Stuart Rich Chief Medical Officer, Director | Dec 4, 2025 | Buy | +2,500 | $9.20 | $23.00K | 2,500 |
| Stuart Rich Chief Medical Officer, Director | Dec 3, 2025 | Buy | +1,500 | $9.08 | $13.62K | 2,766 |
| Stuart Rich Chief Medical Officer, Director | Dec 2, 2025 | Buy | +1,000 | $9.01 | $9.01K | 1,266 |
| Christopher Thomas Giordano CEO, Director | Nov 20, 2025 | Buy | +538 | $7.59 | $4.08K | 2,605 |
| Christopher Thomas Giordano CEO, Director | Nov 19, 2025 | Buy | +455 | $7.51 | $3.42K | 2,067 |
| Christopher Thomas Giordano CEO, Director | Nov 18, 2025 | Buy | +1,612 | $7.75 | $12.49K | 1,612 |
| June Sherie Almenoff Director | Nov 18, 2025 | Buy | +1,900 | $7.52 | $14.29K | 1,993 |
| June Sherie Almenoff Director | Nov 18, 2025 | Buy | +1,900 | $7.52 | $14.29K | 1,993 |
| June Sherie Almenoff Director | Nov 17, 2025 | Buy | +93 | $7.15 | $665 | 93 |
| June Sherie Almenoff Director | Nov 17, 2025 | Buy | +93 | $7.15 | $665 | 93 |
| Thomas McGauley Interim CFO | Nov 17, 2025 | Buy | +2,000 | $7.34 | $14.68K | 2,000 |
| Thomas McGauley Interim CFO | Nov 17, 2025 | Buy | +1,000 | $7.35 | $7.35K | 1,000 |
| Thomas McGauley Interim CFO | Nov 17, 2025 | Buy | +5,000 | $7.23 | $36.15K | 5,000 |
| Gerald T. Proehl Director | Aug 8, 2024 | Buy | +1,666 | – | – | 1,667 |
| Michael H. Davidson Director | Aug 8, 2024 | Buy | +2,500 | – | – | 2,881 |
| Stuart Rich Chief Medical Officer, Director, 10% owner | Sep 21, 2022 | Gift | +1,909,585 | – | – | 1,909,585 |
| Stuart Rich Chief Medical Officer, Director, 10% owner | Sep 21, 2022 | Gift | −1,909,585 | – | – | 424,347 |
| Declan Doogan Director, 10% owner | Aug 11, 2022 | Gift | −567,871 | – | – | 0 |
| Declan Doogan Director, 10% owner | Aug 11, 2022 | Gift | +567,871 | – | – | 3,637,871 |
| Stuart Rich Chief Medical Officer, Director, 10% owner | Nov 29, 2021 | Gift | −1,909,585 | – | – | 0 |
| Stuart Rich Chief Medical Officer, Director, 10% owner | Nov 29, 2021 | Gift | +1,909,585 | – | – | 1,909,585 |
| Stuart Rich Chief Medical Officer, Director, 10% owner | Oct 12, 2021 | Gift | −1,909,585 | – | – | 2,333,932 |
| Stuart Rich Chief Medical Officer, Director, 10% owner | Oct 12, 2021 | Gift | +1,909,585 | – | – | 1,909,585 |
| Declan Doogan Director, 10% owner | Jun 30, 2021 | Gift | −567,871 | – | – | 2,502,129 |
| Stuart Rich Chief Medical Officer, Director, 10% owner | Jun 11, 2021 | Option exercise | +3,581,000 | – | – | 4,243,517 |
| Michael H. Davidson Director | Jun 11, 2021 | Award | +512,000 | – | – | 606,645 |
| Declan Doogan Director, 10% owner | Jun 11, 2021 | Option exercise | +3,070,000 | – | – | 3,637,871 |
| Stuart Rich Chief Medical Officer | Jan 15, 2021 | Award | +3,581 | – | – | 3,581 |
| Stuart Rich Chief Medical Officer | Jan 15, 2021 | Award | +662,517 | – | – | 662,517 |
| Capital Master Fund Ltd. Armistice Director, 10% owner | Sep 8, 2020 | Buy | +8,543 | $1.46 | $12.47K | 2,019,995 |
| Capital Master Fund Ltd. Armistice Director, 10% owner | Sep 8, 2020 | Buy | +0 | – | – | 2,019,995 |
| Capital Master Fund Ltd. Armistice Director, 10% owner | Sep 4, 2020 | Buy | +0 | – | – | 2,011,452 |
| Capital Master Fund Ltd. Armistice Director, 10% owner | Sep 4, 2020 | Buy | +23,457 | $1.41 | $33.07K | 2,011,452 |
| Armistice Capital, Llc Director, 10% owner | Sep 3, 2020 | Buy | +0 | – | – | 1,987,995 |
| Armistice Capital, Llc Director, 10% owner | Sep 3, 2020 | Buy | +36,000 | $1.39 | $50.04K | 1,987,995 |
| Armistice Capital, Llc Director, 10% owner | Sep 2, 2020 | Buy | +20,000 | $1.47 | $29.40K | 1,951,995 |
| Armistice Capital, Llc Director, 10% owner | Sep 2, 2020 | Buy | +0 | – | – | 1,951,995 |
| Armistice Capital, Llc Director, 10% owner | Sep 1, 2020 | Buy | +0 | – | – | 1,931,995 |
| Armistice Capital, Llc Director, 10% owner | Sep 1, 2020 | Buy | +30,000 | $1.46 | $43.80K | 1,931,995 |
| Armistice Capital, Llc Director, 10% owner | Aug 31, 2020 | Buy | +20,000 | $1.45 | $29.00K | 1,901,995 |
| Armistice Capital, Llc Director, 10% owner | Aug 31, 2020 | Buy | +0 | – | – | 1,901,995 |
| Armistice Capital, Llc Director, 10% owner | Aug 27, 2020 | Buy | +12,000 | $1.50 | $18.00K | 1,881,995 |
| Armistice Capital, Llc Director, 10% owner | Aug 27, 2020 | Buy | +0 | – | – | 1,881,995 |
| Armistice Capital, Llc 10% owner | Aug 26, 2020 | Buy | +12,000 | $1.50 | $18.00K | 1,869,995 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.